<DOC>
	<DOCNO>NCT01181193</DOCNO>
	<brief_summary>This non-randomized phase 2 study ass efficacy toxicity long term high dose vitamin D3 give concurrently chemo-radiotherapy ( CCRT ) contain temozolomide follow adjuvant chemotherapy ( ACT ) temozolomide patient newly diagnose glioblastoma multiforme GBM ) . Preoperative diagnosis GBM base magnetic resonance imaging ( MRI ) brain scan . All patient underwent craniotomy partial total resection visible tumour mass . All patient plan postoperative three-dimensional conformal RT ( 3-DCRT ) intensity-modulated RT ( IMRT ) residual tumour and/or resection bed . A total RT dose 54-60 Gy deliver use 2 Gy daily fraction give 5 day week . Daily chemotherapy temozolomide dose 75 mg/m2/day start first day RT , continue entire period RT inclusive week-end break . ACT contain 6 cycle oral temozolomide 150-200 mg/m2/day give 5 day every 4 week . Oral vitamin D3 administer daily dose 4000 IU . Vitamin D3 therapy start 1 week prior commence CCRT , terminate immediately complete last cycle ACT . MRI scan brain perform 4 month complete CCRT , repeat every 4 month first 2 year , every 6 month subsequent year . The study participant follow disease progression death . The study expect complete within 4 year .</brief_summary>
	<brief_title>Vitamin D Treatment Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>1 . Age &gt; 18 year 2 . Newlydiagnosed , histologically confirm GBM 3 . Surgical procedure : craniotomy gross tumour resection maximal debulking 4 . Brain lesion suitable suitable radical 3DCRT/IMRT accord tumour location size . 5 . Karnofsky performance status ( KPS ) &gt; 70 ( ECOG/WHO 01 ) 6 . No previous RT brain 7 . No serious comorbid condition 8 . No treatment biological response modifier cytotoxic agent within four week prior study entry 9 . No participation clinical trial use investigational drug device within four week prior study entry 10 . No serious complication malignant condition 11 . No previous concurrent malignancy site , except cone biopsied situ carcinoma uterine cervix adequately treat basal cell squamous cell carcinoma skin 12 . Adequate organ function evidence follow peripheral blood count serum chemistry study entry : Hemoglobin &gt; 9.0 Gm/dL WBC count &gt; 4.0x109/L Neutrophile count &gt; 1.5 cell x 109/L , Platelet count &gt; 100 x 109/L , Creatinine &lt; 1.5 mg/dL Total bilirubin &lt; ULN ( upper limit normal ) AST/SGOT &lt; ULN Calcium &lt; ULN 13 . Ability sign inform consent 14 . Ability attend followup visit 1 . Surgical procedure : stereotactic biopsy 2 . Brain lesion suitable 3DCRT/IMRT 3 . KPS &lt; 70 ( ECOG/WHO &lt; 2 ) 4 . Previous RT brain 5 . Treatment biological response modifier cytotoxic agent within four week prior study entry 6 . Participation clinical trial use investigational drug device within 7 week prior study entry 7 . Major surgical procedure within two week prior study entry 8 . Serious comorbid condition , inclusive limited myocardial infarction within previous six month , uncontrolled cardiac arrhythmia , uncontrolled angina pectoris , active infection include acute hepatitis 9 . Serious complication malignant condition 10 . Previous concurrent malignancy 11 . Known hypersensitivity vitamin D 12 . Inadequate organ function evidence follow peripheral blood count serum chemistry study entry : Hemoglobin &lt; 9.0 Gm/dL WBC count &lt; 4.0x109/L Neutrophile count &lt; 1.5 cell x 109/L , Platelet count &lt; 100 x 109/L , Creatinine &gt; 1.5 mg/dL Total bilirubin &gt; ULN ( upper limit normal ) AST/SGOT &gt; ULN Calcium &gt; ULN 13 . Inability sign inform consent 14 . Psychological , familial , sociological geographical condition permit regular medical followup compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>glioblastoma multiforme</keyword>
	<keyword>chemoradiotherapy</keyword>
	<keyword>vitamin D</keyword>
</DOC>